Boris Johnson COVID Briefing

The transcript discusses reports of a rare blood clot, CSVT, occurring after AstraZeneca COVID-19 vaccination. While investigations are ongoing, no causal link has been established, and the occurrence is extremely rare. The MHRA advises seeking medical attention for specific symptoms and emphasizes that the vaccine's benefits outweigh the risks. The public is encouraged to report side effects through the Yellow Card scheme.

What is the rare form of blood clot reported after AstraZeneca vaccination?

• Pulmonary embolism

• Deep vein thrombosis

• Coronary artery thrombosis

• Cerebral sinus vein thrombosis

What should individuals do if they experience a headache lasting more than four days after vaccination?

• Ignore it

• Take over-the-counter pain medication

• Wait for a week

• Seek medical attention

What is the current status of the investigation into the blood clot cases?

• Investigation is complete

• Investigation is ongoing

• Investigation is inconclusive

• Investigation has not started

What does the MHRA conclude about the benefits of the AstraZeneca vaccine?

• Benefits are equal to the risks

• Benefits outweigh the risks

• Benefits are negligible

• Risks outweigh the benefits

How can individuals report suspected side effects of COVID-19 vaccines?

• Through the Yellow Card scheme

• By calling a hotline

• By visiting a hospital

• Through social media